Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblastoma patients.
Connelly explained that glioblastoma, the most common malignant brain tumour, significantly impacts brain function, highlighting the importance of clinical trials to improve patient quality of life.
The trial, opened nearly two years ago, investigates gallium maltolate, an oral medication showing promise in preclinical studies and animal models for efficacy against tumour cells. This phase focuses on drug tolerance, with patients reporting ease of use compared to traditional treatments and the ability to maintain normal daily activities.
An expanded access programme (EAP), also known as compassionate use, has been launched by IA-AI subsidiary Imaging Biometric to allow wider access to gallium maltolate across the country, benefiting patients unable to travel to the Medical College of Wisconsin. The EAP, approved by the FDA, aims to collect additional safety and toxicity data, contributing to the trial's findings and supporting the progression towards a phase two clinical trial.
The next milestone, by the end of 2024, involves concluding the phase one trial, determining the maximum tolerated dose, and preparing for the phase two trial slated for 2025, focusing on safety and beginning to evaluate efficacy.
Contact Details
Proactive UK
Proactive UK
+44 20 7989 0813
